Harrison Litvack, Co-Founder
Clinical trials are more than just research. They are the primary method for companies and researchers to test new inventions and develop new medical treatments and diagnostics. However, the recruitment and retention process in clinical trials has always been a constant challenge for sponsors, sites, and CROs, with a limited number of volunteers available to participate. According to the National Institutes of Health, more than 80% of clinical trials in the United States fail to meet their patient recruitment timelines. These delays result in high financial losses, depleted resources, and prolonged time to market introduction.
TrialTech Medical, a software solutions and screening services provider, is perfectly poised to address these challenges. The company enhances subject recruitment, screening, enrollment, and site management for clinical research studies worldwide. Co-founded by brothers Harrison and William Litvack, the company introduces equity into the clinical trial recruitment process by increasing awareness of research studies among potential participants regardless of where they live or receive medical care. “We are leading the clinical trial recruitment and enrollment process into the 21st century,” asserts Harrison Litvack, Co-Founder at TrialTech Medical.
Harrison explained to Pharma Tech Outlook that the clinical trial industry remains behind the times in terms of its capabilities in digital targeting and recruitment. TrialTech utilizes state-of-the-art AI-driven digital targeting and a two-stage screening process to identify and refer qualified candidates to clinical sites. This allows for a much more efficient use of marketing budgets than conventional recruitment methods like posters, brochures, radio spots, and traditional TV advertisements.
For clinical trial sponsors, the company accelerates enrollment by expanding recruitment to potential participants who might lack access to trial sites or not know about the study in the first place. Moreover, TrialTech also reduces site frustration and inundation by providing high quality referrals through its rigorous, two-phase, digital and telephonic pre-screening process.
Jesse Bendetson, Vice President of Operations
According to Vice President of Operations Jesse Bendetson, “TrialTech targets patients on a trial-specific basis so that our algorithms function within a given study’s specific inclusion and exclusion criteria. As such, we can reduce noise and refer patients with both high sensitivity and high specificity. This reduces the screening burden on sites, and especially the costs associated with on-site screen failures for low-likelihood patients.”
But TrialTech is more than just a patient recruitment company. TrialTech also has a proprietary software package that allows site coordinators centralized access to screening data, contact information, and medical records. Moreover, TrialTech’s HIPAA-compliant software platform facilitates streamlined communication between stakeholders by providing sponsors with anonymized patient tracking throughout the recruitment funnel and real-time metrics on ROI for adjustment of digital marketing spend. “Our goal is to enhance the clinical trial ecosystem and help bring new therapies to patients in a timely and cost-effective manner,” explains Bendetson.
Despite being a relatively new entrant into the market, TrialTech has been garnering massive traction due to the quality of its services. For instance, the company recently helped a client overcome recruiting challenges for a trial in Duchenne muscular dystrophy (DMD), an extremely rare genetic disease affecting boys and young men. TrialTech was able to target and screen more than 4% of the entire United States DMD population for just over $11,000 in marketing spend.
Today, TrialTech caters to the pharmaceutical, biotechnology, and medical device industries. The company has experience recruiting for cardiovascular, neuromuscular, and musculoskeletal trials and recently expanded its efforts into the oncology space as well. “For the future, we want to develop our knowledge base in different therapeutic areas and build out more robust databases, which will allow us to further refine our trial-specific audience targeting strategies. We also aim to expand our market reach with more trials and area-specific experience,” concludes Litvack.